Revision as of 07:35, 11 November 2023 edit Vaccinationist (talk \| contribs) Extended confirmed users 4,688 edits skeletal formulae Tag: 2017 wikitext editor ← Previous edit		Latest revision as of 04:47, 15 July 2024 edit undo Whywhenwhohow (talk \| contribs) Autopatrolled, Extended confirmed users, Pending changes reviewers 45,400 edits infobox
Line 4: {{cs1 config \|name-list-style=vanc \|display-authors=6}} {{Infobox drug ~~\| drug_name =~~ \| type = combo \| image = Decitabine and cedazuridine.svg Line 17 ⟶ 16: <!-- Clinical data --> ~~\| pronounce =~~ \| tradename = Inqovi, Inaqovi \| Drugs.com = {{Drugs.com\|monograph\|decitabine-and-cedazuridine}} \| MedlinePlus = a620050 ~~\| licence_CA = <!-- Health Canada may use generic or brand name (generic name preferred) -->~~ ~~\| licence_EU = <!-- EMA uses INN (or special INN_EMA) -->~~ \| DailyMedID = Cedazuridine and decitabine ~~\| licence_US = <!-- FDA may use generic or brand name (generic name preferred) -->~~ \| pregnancy_AU = X \| pregnancy_AU_comment = <ref>{{cite web \| title = Australian Public Assessment Report for Decitabine and cedazuridine \| url = https://www.tga.gov.au/sites/default/files/auspar-decitabine-cedazuridine-210128.pdf \| date = January 2021 \| work = Therapeutic Goods Administration \| publisher = The Australian Government \| access-date = 13 June 2021 \| archive-date = 13 June 2021 \| archive-url = https://web.archive.org/web/20210613065649/https://www.tga.gov.au/sites/default/files/auspar-decitabine-cedazuridine-210128.pdf \| url-status = live }}</ref> \| pregnancy_category = Not recommended \| routes_of_administration = [[Oral administration\|By mouth]] ~~\| ATCvet =~~ \| ATC_prefix = None \| ATC_suffix =

Decitabine/cedazuridine: Difference between revisions